
    
      Primary Objective(s)

        -  To assess feasibility and safety of combination of perioperative 177Lu Dotatate and
           cytoreductive surgery in metastatic GEP NETs Secondary Objective(s)

        -  To assess response rate (RR) after 2 cycles 177Lu Dotatate

        -  To assess recurrence free survival (RFS) of the overall treatment strategy

        -  To assess overall survival (OS) of the overall treatment strategy
    
  